Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the deve… Read more
Danaher Corporation (DHR) - Net Assets
Latest net assets as of September 2025: $51.07 Billion USD
Based on the latest financial reports, Danaher Corporation (DHR) has net assets worth $51.07 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($79.90 Billion) and total liabilities ($28.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $51.07 Billion |
| % of Total Assets | 63.92% |
| Annual Growth Rate | 19.36% |
| 5-Year Change | 24.57% |
| 10-Year Change | 108.51% |
| Growth Volatility | 15.69 |
Danaher Corporation - Net Assets Trend (1985–2024)
This chart illustrates how Danaher Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Danaher Corporation (1985–2024)
The table below shows the annual net assets of Danaher Corporation from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $49.55 Billion | -7.37% |
| 2023-12-31 | $53.49 Billion | +6.79% |
| 2022-12-31 | $50.09 Billion | +10.88% |
| 2021-12-31 | $45.18 Billion | +13.58% |
| 2020-12-31 | $39.78 Billion | +31.36% |
| 2019-12-31 | $30.28 Billion | +7.28% |
| 2018-12-31 | $28.23 Billion | +7.05% |
| 2017-12-31 | $26.37 Billion | +14.26% |
| 2016-12-31 | $23.08 Billion | -2.89% |
| 2015-12-31 | $23.76 Billion | +1.34% |
| 2014-12-31 | $23.45 Billion | +4.45% |
| 2013-12-31 | $22.45 Billion | +17.65% |
| 2012-12-31 | $19.08 Billion | +12.44% |
| 2011-12-31 | $16.97 Billion | +23.23% |
| 2010-12-31 | $13.77 Billion | +18.42% |
| 2009-12-31 | $11.63 Billion | +18.57% |
| 2008-12-31 | $9.81 Billion | +7.96% |
| 2007-12-31 | $9.09 Billion | +36.74% |
| 2006-12-31 | $6.64 Billion | +30.79% |
| 2005-12-31 | $5.08 Billion | +9.97% |
| 2004-12-31 | $4.62 Billion | +26.68% |
| 2003-12-31 | $3.65 Billion | +21.17% |
| 2002-12-31 | $3.01 Billion | +35.05% |
| 2001-12-31 | $2.23 Billion | +14.74% |
| 2000-12-31 | $1.94 Billion | +13.67% |
| 1999-12-31 | $1.71 Billion | +26.41% |
| 1998-12-31 | $1.35 Billion | +47.43% |
| 1997-12-31 | $916.90 Million | +14.57% |
| 1996-12-31 | $800.30 Million | +36.50% |
| 1995-12-31 | $586.30 Million | +23.15% |
| 1994-12-31 | $476.10 Million | +30.90% |
| 1993-12-31 | $363.70 Million | +4.39% |
| 1992-12-31 | $348.40 Million | +9.11% |
| 1991-12-31 | $319.30 Million | +4.69% |
| 1990-12-31 | $305.00 Million | +59.10% |
| 1989-12-31 | $191.70 Million | +23.12% |
| 1988-12-31 | $155.70 Million | +50.73% |
| 1987-12-31 | $103.30 Million | +58.44% |
| 1986-12-31 | $65.20 Million | +30.66% |
| 1985-12-31 | $49.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Danaher Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4429930000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $44.19 Billion | 89.19% |
| Common Stock | $9.00 Million | 0.02% |
| Other Comprehensive Income | $-3.22 Billion | -6.50% |
| Other Components | $8.56 Billion | 17.29% |
| Total Equity | $49.54 Billion | 100.00% |
Danaher Corporation Competitors by Market Cap
The table below lists competitors of Danaher Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
British American Tobacco p.l.c.
NYSE:BTI
|
$123.65 Billion |
|
S&P Global Inc
NYSE:SPGI
|
$124.01 Billion |
|
State Bank of India
PINK:SBKFF
|
$125.51 Billion |
|
UNILEVER PLC LS -,035
XETRA:UNV0
|
$126.11 Billion |
|
Accenture plc
NYSE:ACN
|
$121.95 Billion |
|
Bristol-Myers Squibb Company
NYSE:BMY
|
$121.36 Billion |
|
Stryker Corporation
NYSE:SYK
|
$121.03 Billion |
|
Newmont Goldcorp Corp
NYSE:NEM
|
$120.92 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Danaher Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 53,486,000,000 to 49,543,000,000, a change of -3,943,000,000 (-7.4%).
- Net income of 3,899,000,000 contributed positively to equity growth.
- Dividend payments of 768,000,000 reduced retained earnings.
- Share repurchases of 5,979,000,000 reduced equity.
- New share issuances of 162,000,000 increased equity.
- Other comprehensive income decreased equity by 1,470,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.90 Billion | +7.87% |
| Dividends Paid | $768.00 Million | -1.55% |
| Share Repurchases | $5.98 Billion | -12.07% |
| Share Issuances | $162.00 Million | +0.33% |
| Other Comprehensive Income | $-1.47 Billion | -2.97% |
| Other Changes | $213.00 Million | +0.43% |
| Total Change | $- | -7.37% |
Book Value vs Market Value Analysis
This analysis compares Danaher Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1251.85x to 2.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.16 | $195.21 | x |
| 1986-12-31 | $0.19 | $195.21 | x |
| 1987-12-31 | $0.27 | $195.21 | x |
| 1988-12-31 | $0.40 | $195.21 | x |
| 1989-12-31 | $0.51 | $195.21 | x |
| 1990-12-31 | $0.73 | $195.21 | x |
| 1991-12-31 | $0.72 | $195.21 | x |
| 1992-12-31 | $0.77 | $195.21 | x |
| 1993-12-31 | $0.82 | $195.21 | x |
| 1994-12-31 | $1.03 | $195.21 | x |
| 1995-12-31 | $1.23 | $195.21 | x |
| 1996-12-31 | $1.47 | $195.21 | x |
| 1997-12-31 | $1.56 | $195.21 | x |
| 1998-12-31 | $2.35 | $195.21 | x |
| 1999-12-31 | $2.92 | $195.21 | x |
| 2000-12-31 | $3.34 | $195.21 | x |
| 2001-12-31 | $3.67 | $195.21 | x |
| 2002-12-31 | $4.75 | $195.21 | x |
| 2003-12-31 | $5.64 | $195.21 | x |
| 2004-12-31 | $7.05 | $195.21 | x |
| 2005-12-31 | $7.74 | $195.21 | x |
| 2006-12-31 | $10.21 | $195.21 | x |
| 2007-12-31 | $13.79 | $195.21 | x |
| 2008-12-31 | $14.60 | $195.21 | x |
| 2009-12-31 | $17.32 | $195.21 | x |
| 2010-12-31 | $20.07 | $195.21 | x |
| 2011-12-31 | $24.11 | $195.21 | x |
| 2012-12-31 | $26.67 | $195.21 | x |
| 2013-12-31 | $31.48 | $195.21 | x |
| 2014-12-31 | $32.65 | $195.21 | x |
| 2015-12-31 | $33.44 | $195.21 | x |
| 2016-12-31 | $32.87 | $195.21 | x |
| 2017-12-31 | $37.33 | $195.21 | x |
| 2018-12-31 | $39.73 | $195.21 | x |
| 2019-12-31 | $41.72 | $195.21 | x |
| 2020-12-31 | $55.33 | $195.21 | x |
| 2021-12-31 | $61.30 | $195.21 | x |
| 2022-12-31 | $67.94 | $195.21 | x |
| 2023-12-31 | $71.98 | $195.21 | x |
| 2024-12-31 | $67.20 | $195.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Danaher Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.87%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.33%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.57x
- Recent ROE (7.87%) is below the historical average (13.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 11.22% | 1.88% | 1.11x | 5.39x | $610.00K |
| 1986 | 13.34% | 1.95% | 0.60x | 11.36x | $2.18 Million |
| 1987 | 19.46% | 3.27% | 0.94x | 6.34x | $9.77 Million |
| 1988 | 25.05% | 5.46% | 1.24x | 3.70x | $23.43 Million |
| 1989 | 31.87% | 8.16% | 1.48x | 2.65x | $41.93 Million |
| 1990 | 11.70% | 4.25% | 1.13x | 2.44x | $5.20 Million |
| 1991 | 4.17% | 1.60% | 1.13x | 2.30x | $-18.63 Million |
| 1992 | 9.07% | 3.33% | 1.23x | 2.21x | $-3.24 Million |
| 1993 | 4.87% | 1.66% | 1.22x | 2.40x | $-18.67 Million |
| 1994 | 17.16% | 6.34% | 1.14x | 2.38x | $34.09 Million |
| 1995 | 18.49% | 7.29% | 1.00x | 2.53x | $49.77 Million |
| 1996 | 25.97% | 11.47% | 1.03x | 2.21x | $127.77 Million |
| 1997 | 16.88% | 7.55% | 1.09x | 2.05x | $63.11 Million |
| 1998 | 13.53% | 6.29% | 1.06x | 2.03x | $47.72 Million |
| 1999 | 15.31% | 8.18% | 1.05x | 1.78x | $90.72 Million |
| 2000 | 16.69% | 8.58% | 0.94x | 2.08x | $129.98 Million |
| 2001 | 13.36% | 7.87% | 0.78x | 2.16x | $74.81 Million |
| 2002 | 9.65% | 6.34% | 0.76x | 2.00x | $-10.57 Million |
| 2003 | 14.72% | 10.14% | 0.77x | 1.89x | $172.16 Million |
| 2004 | 16.15% | 10.83% | 0.81x | 1.84x | $284.03 Million |
| 2005 | 17.67% | 11.24% | 0.87x | 1.80x | $389.76 Million |
| 2006 | 16.89% | 11.69% | 0.75x | 1.94x | $457.56 Million |
| 2007 | 13.43% | 11.07% | 0.63x | 1.92x | $311.70 Million |
| 2008 | 13.43% | 10.38% | 0.73x | 1.78x | $336.77 Million |
| 2009 | 9.90% | 10.30% | 0.57x | 1.68x | $-11.31 Million |
| 2010 | 13.08% | 13.58% | 0.59x | 1.62x | $421.90 Million |
| 2011 | 11.66% | 12.25% | 0.54x | 1.77x | $280.09 Million |
| 2012 | 12.09% | 12.59% | 0.55x | 1.73x | $396.85 Million |
| 2013 | 12.04% | 14.10% | 0.55x | 1.55x | $456.47 Million |
| 2014 | 11.11% | 13.05% | 0.54x | 1.58x | $260.59 Million |
| 2015 | 10.96% | 17.99% | 0.30x | 2.04x | $227.87 Million |
| 2016 | 11.10% | 15.13% | 0.37x | 1.97x | $253.42 Million |
| 2017 | 9.45% | 13.60% | 0.39x | 1.77x | $-143.72 Million |
| 2018 | 9.40% | 15.55% | 0.36x | 1.70x | $-170.54 Million |
| 2019 | 8.45% | 14.28% | 0.29x | 2.05x | $-469.86 Million |
| 2020 | 9.17% | 16.36% | 0.29x | 1.92x | $-330.60 Million |
| 2021 | 14.24% | 21.84% | 0.35x | 1.84x | $1.92 Billion |
| 2022 | 14.39% | 27.06% | 0.32x | 1.68x | $2.20 Billion |
| 2023 | 8.87% | 19.85% | 0.28x | 1.58x | $-605.60 Million |
| 2024 | 7.87% | 16.33% | 0.31x | 1.57x | $-1.06 Billion |
Industry Comparison
This section compares Danaher Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Danaher Corporation (DHR) | $51.07 Billion | 11.22% | 0.56x | $122.79 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |